These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20428379)

  • 21. A new oral vaccine candidate based on the microencapsulation by spray-drying of inactivated Vibrio cholerae.
    Año G; Esquisabel A; Pastor M; Talavera A; Cedré B; Fernández S; Sifontes S; Aranguren Y; Falero G; García L; Solís RL; Pedraz JL
    Vaccine; 2011 Aug; 29(34):5758-64. PubMed ID: 21683110
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population-Level Effect of Cholera Vaccine on Displaced Populations, South Sudan, 2014.
    Azman AS; Rumunu J; Abubakar A; West H; Ciglenecki I; Helderman T; Wamala JF; Vázquez Ode L; Perea W; Sack DA; Legros D; Martin S; Lessler J; Luquero FJ
    Emerg Infect Dis; 2016 Jun; 22(6):1067-70. PubMed ID: 27192187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholera vaccines.
    Ryan ET; Calderwood SB
    Clin Infect Dis; 2000 Aug; 31(2):561-5. PubMed ID: 10987721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Home-grown Vietnamese cholera vaccine "completely safe".
    Quirk M
    Lancet Infect Dis; 2002 Apr; 2(4):198. PubMed ID: 11937407
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunogenicity of Vibrio cholerae outer membrane vesicles secreted at various environmental conditions.
    Adriani R; Mousavi Gargari SL; Nazarian S; Sarvary S; Noroozi N
    Vaccine; 2018 Jan; 36(2):322-330. PubMed ID: 29191736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
    Viret JF; Dietrich G; Favre D
    Vaccine; 2004 Jun; 22(19):2457-69. PubMed ID: 15193410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG DNA, liposome and refined antigen oral cholera vaccine.
    Leelawongtawon R; Somroop S; Chaisri U; Tongtawe P; Chongsa-nguan M; Kalambaheti T; Tapchaisri P; Pichyangkul S; Sakolvaree Y; Kurazono H; Hayashi H; Chaicumpa W
    Asian Pac J Allergy Immunol; 2003 Dec; 21(4):231-9. PubMed ID: 15198341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunity in experimental cholera: effect of parenteral immunization with vaccines and toxoid.
    Sinha VB; Bhaskaran K
    Bull World Health Organ; 1973; 49(6):605-13. PubMed ID: 4548387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El tor inaba three months after vaccination.
    Tacket CO; Cohen MB; Wasserman SS; Losonsky G; Livio S; Kotloff K; Edelman R; Kaper JB; Cryz SJ; Giannella RA; Schiff G; Levine MM
    Infect Immun; 1999 Dec; 67(12):6341-5. PubMed ID: 10569747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR.
    Albert MJ; Alam K; Ansaruzzaman M; Qadri F; Sack RB
    J Infect Dis; 1994 Jan; 169(1):230-1. PubMed ID: 8277193
    [No Abstract]   [Full Text] [Related]  

  • 31. Sublingual Adjuvant Delivery by a Live Attenuated Vibrio cholerae-Based Antigen Presentation Platform.
    Liao J; Gibson JA; Pickering BS; Watnick PI
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29875145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral immunogenicity of the inactivated Vibrio cholerae whole-cell vaccine encapsulated in biodegradable microparticles.
    Yeh MK; Liu YT; Chen JL; Chiang CH
    J Control Release; 2002 Aug; 82(2-3):237-47. PubMed ID: 12175740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.
    Tacket CO; Losonsky G; Nataro JP; Cryz SJ; Edelman R; Fasano A; Michalski J; Kaper JB; Levine MM
    J Infect Dis; 1993 Dec; 168(6):1536-40. PubMed ID: 8245542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploiting cholera vaccines as a versatile antigen delivery platform.
    Silva AJ; Eko FO; Benitez JA
    Biotechnol Lett; 2008 Apr; 30(4):571-9. PubMed ID: 18008168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Live oral cholera vaccine: evaluation of the clinical effectiveness of two strains in humans.
    Cash RA; Music SI; Libonati JP; Schwartz AR; Hornick RB
    Infect Immun; 1974 Oct; 10(4):762-4. PubMed ID: 4426706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review of the current status of enteric vaccines.
    Levine MM; Noriega F
    P N G Med J; 1995 Dec; 38(4):325-31. PubMed ID: 9522876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholera vaccine will reduce antibiotic use.
    Okeke IN
    Science; 2009 Aug; 325(5941):674. PubMed ID: 19661401
    [No Abstract]   [Full Text] [Related]  

  • 38. Live oral vaccines against cholera: an update.
    Levine MM; Kaper JB
    Vaccine; 1993; 11(2):207-12. PubMed ID: 8438619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity of liposome-associated oral cholera vaccine prepared from combined Vibrio cholerae antigens.
    Chaicumpa W; Parairo JR; New RC; Pongponratn E; Ruangkunaporn Y; Tapchaisri P; Chongsa-nguan M
    Asian Pac J Allergy Immunol; 1990 Dec; 8(2):87-94. PubMed ID: 2091663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moving forward with an imperfect vaccine.
    Pezzoli L; Azman AS
    Lancet Infect Dis; 2021 Oct; 21(10):1339-1341. PubMed ID: 34146474
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.